Aktuelle Kardiologie 2012; 1(04/05): 260-267
DOI: 10.1055/s-0032-1324818
Georg Thieme Verlag KG Stuttgart · New York

Moderne Bildgebung bei Kardiomyopathien

Imaging in Cardiomyopathies
S. Greulich
1   Abteilung Kardiologie, Robert-Bosch-Krankenhaus Stuttgart
J. Schumm
1   Abteilung Kardiologie, Robert-Bosch-Krankenhaus Stuttgart
U. Sechtem
1   Abteilung Kardiologie, Robert-Bosch-Krankenhaus Stuttgart
H. Mahrholdt
1   Abteilung Kardiologie, Robert-Bosch-Krankenhaus Stuttgart
› Author Affiliations
Further Information

Publication History

Publication Date:
16 October 2012 (online)


Während bei ischämischen Kardiomyopathien die Ätiologie durch eine Koronarangiografie normalerweise einfach zu klären ist, stellt die Abklärung nicht ischämischer Kardiomyopathien eine Herausforderung dar. Die Echokardiografie ist dabei diagnostisches Mittel der ersten Wahl. Neben der breiten Verfügbarkeit liegen ihre Stärken in der Quantifizierung systolischer als auch diastolischer Funktionsstörungen sowie in der Erfassung begleitender valvulärer Pathologien. Die CMR ermöglicht eine umfassende funktionelle Darstellung vor allem des rechten Ventrikels mit frei wählbaren Schnittebenen. Insbesondere durch Muster und Ausmaß der Kontrastmittelanreicherung im Myokard (LGE) lassen sich sowohl Aussagen über die vermutliche Ätiologie der CMP als auch über die individuelle Prognose der Patienten treffen. Aufgrund der fehlenden Strahlenbelastung eignet sich die CMR sowohl zur initialen Diagnostik als auch zur Verlaufskontrolle. Die kardiale CT hilft durch die Darstellung der Koronarien, eine relevante KHK als Ursache der kardialen Funktionsstörung auszuschließen.


Ischemic cardiomyopathies are usually easily diagnosed by coronary angiography, while the aetiology of non-ischemic CMP may be challenging to differentiate. Echocardiography remains the first diagnostic tool, due to its availability and its potential to quantify systolic and diastolic dysfunction, as well as concomitant valvular pathologies. CMR has become increasingly important in the last years, as it offers not only a comprehensive functional assessment of the left as well as the right ventricle but also different possibilities of tissue characterization. In particular, the pattern and extent of late gadolinium enhancement provides insights into the underlying pathology, and into the individual patientsʼ prognosis. As CMR works without radiation, it is suitable for initial diagnostic as well as repeated follow-up. The main advantage of CT is the excellent visualization of normal coronary arteries which permits excluding coronary artery disease as the cause of cardiac dysfunction.

  • Literatur

  • 1 Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-276
  • 2 Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82
  • 3 Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-1084
  • 4 Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
  • 5 Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57: 2263-2270
  • 6 Mahrholdt H, Wagner A, Judd RM et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26: 1461-1474
  • 7 Friedrich MG, Sechtem U, Schulz-Menger J et al. for the International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487
  • 8 Iles L, Pfluger H, Phrommintikul A et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52: 1574-1580
  • 9 Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816
  • 10 McCrohon JA, Moon JC, Prasad SK et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium enhanced cardiovascular magnetic resonance. Circulation 2003; 108: 54-59
  • 11 Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977-1985
  • 12 Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320
  • 13 Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 875-887
  • 14 Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. Circulation 2011; 124: 2761-2796
  • 15 Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121: 1533-1541
  • 16 Tandri H, Macedo R, Calkins H et al. Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. Am Heart J 2008; 155: 147-153
  • 17 Tandri H, Saranathan M, Rodriguez ER et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 98-103
  • 18 Petersen SE, Selvanayagam JB, Wiesmann F et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 101-105
  • 19 Grün S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59: 1604-1615
  • 20 Ong P, Athansiadis A, Hill S et al. Usefulness of pericardial effusion as new diagnostic criterion for noninvasive detection of myocarditis. Am J Cardiol 2011; 108: 445-452
  • 21 Patel MR, Cawley PJ, Heitner JF et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-1977
  • 22 Selvanayagam JB, Hawkins PN, Paul B et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50: 2101-2110
  • 23 Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022-1030
  • 24 Tanner MA, Galanello R, Dessi C et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884
  • 25 Anderson LJ. Assessment of iron overload with T2* magnetic resonance imaging. Prog Cardiovasc Dis 2011; 54: 287-294